Le Lézard
Classified in: Health
Subject: PLW

New U.S. Patent Allowance Granted to Mastix LLC for a New Chewing Gum Manufacturing Method Incorporating Cannabinoids


HUNT VALLEY, Md., July 25, 2017 /PRNewswire/ -- Mastix LLC, a leading manufacturer of innovative functional supplement products, today announces that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Application 14/732,072, a utility patent that claims a new manufacturing method for functional chewing gum that covers powder and oil-based active ingredients, including cannabidiol (CBD) and tetrahydrocannabinol (THC). This platform patent technology covers the inclusion of a wide range of active ingredients, including cannabinoids (both naturally extracted and synthetically derived), which is a market experiencing explosive growth.

"The granting of this notice of allowance for our novel chewing gum dosage form validates the innovative nature of our platform technology and positions us well to offer our customers and consumers an alternative delivery system to pills, capsules and beverages that is widely acceptable and very familiar," said Bob Estey, CEO of Mastix. "We have the unique ability to incorporate either a single active ingredient, or multiple active ingredients, into the gum tablets we make to provide our customers with truly custom chewing gum products that will now be patent protected. Consumers are actively seeking alternative delivery vehicles for the many pharmaceutical and supplement products they currently take as pills or capsules. Chewing gum is a convenient and discrete way for consumers to quickly and efficiently deliver the benefits they expect from the products they use to improve their health and wellness. The extensive clinical studies the US Military performed on our caffeine gum proved that gum delivered through the oral mucosa is up to five times faster than swallowing pills or capsules while also maintaining high bioavailability of the active."

In addition to its proprietary CBD gum (www.medcbdx.com), Mastix offers custom development, contract manufacturing and private label for its chewing gum, lozenge and chewable tablet products. Mastix has developed tableted products in a wide range of active ingredients including dietary supplements, herbal extracts, probiotics and cannabinoids, and is best known as the supplier of caffeine chewing gum for the US Military ration kits.

About Mastix LLC
Mastix LLC develops, manufactures and markets niche functional food and dietary supplement products in chewing gum, chewable tablet and lozenge dosage formats. Mastix manufactures its products in full compliance with FDA GMP regulations.

FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE: The statements presented in this press release have not been evaluated by the FDA and are not intended to diagnose, treat, cure or prevent any disease.

LEGAL DISCLOSURE
Mastix LLC does not develop, manufacture, sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA).

This press release was issued through 24-7PressRelease.com. For further information, visit http://www.24-7pressrelease.com.

 

SOURCE Mastix LLC


These press releases may also interest you

at 00:39
World Malaria Day is marked each year on April 25. World Health Organization (WHO) gave as the theme for World Malaria Day 2024 Accelerating the fight against malaria for a more equitable world. WHO stated that malaria not only continues to directly...

25 avr 2024
The report titled "Anti-Adhesion Products Market by Product Type (Natural Adhesion Barriers, Synthetic Adhesion Barriers), Product Form (Film Formulation, Gel Formulation, Liquid Formulation), Application, End-User - Global Forecast 2024-2030" is now...

25 avr 2024
Product: Meat and vegetable products Issue: Food - Microbial Contamination - Listeria Distribution:British Columbia See the affected products and product photos for this recall SOURCE Canadian Food Inspection Agency (CFIA)

25 avr 2024
The report titled "Contract Research Organization Services Market by Type (Clinical Research Services, Consulting Services, Data Management Services), Trial Phase (Phase I, Phase II, Phase III), Therapeutic Area, Molecule Type, End-User - Global...

25 avr 2024
Greenbrook TMS Inc. ("Greenbrook" or the "Company") today announced its fiscal year ended December 31, 2023 ("Fiscal 2023") operational and financial results. All values in this news release are in United States dollars, unless otherwise stated....

25 avr 2024
AIDS Healthcare Foundation applauds the government of Colombia for issuing a compulsory license on HIV drug dolutegravir, which will allow the country to access affordable generic versions of the treatment as an alternative to the costly branded...



News published on and distributed by: